RxDoctor Payments Data

Douglas Tsuchida, MD

Family Medicine · Houston, TXNPI 1922038652

Payments from drug & device makers

$1,268in general payments, 2019–2025

Across 74 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$253
  • GSK$195
  • AstraZeneca$148
  • AbbVie$143
  • Amgen$85
  • Pfizer$82
  • plus $361 from 11 others

What the payments were for

  • Food & beverage$1,23798%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,268 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$107,372
Medicare patients
187
Services billed
1,207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$128,311
FarxigaDapagliflozin Propanediol50$58,616
EliquisApixaban32$33,207
MounjaroTirzepatide11$23,738
JardianceEmpagliflozin16$21,300
SymbicortBudesonide/Formoterol Fumarate18$10,755
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,813
SynthroidLevothyroxine Sodium65$6,191
Tresiba Flextouch U-100Insulin Degludec12$5,802
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$5,069
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$4,714
Rosuvastatin Calcium343$4,070
Nebivolol Hcl57$3,313
Levothyroxine Sodium266$3,279
Atorvastatin Calcium416$3,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$63$128,31186 claims
AstraZenecaFarxiga, Symbicort$148$69,37168 claims
PfizerEliquis, Paxlovid$82$34,63759 claims
Lilly USA, LLCMounjaro$253$23,73811 claims
Boehringer IngelheimJardiance$21$21,30016 claims
GSKTrelegy Ellipta, Anoro Ellipta$195$13,52725 claims
AbbVieSynthroid$143$6,19165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →